Lancet Sub-Journal: Effect of "Star Drug" Liraglutide on Visceral Fat in Overweight and Obese Adults

For obese people who have developed diabetes and coronary heart disease, reducing weight and improving insulin sensitivity are the basis for treatment

Large-scale clinical studies such as LEADER and SUSTAIN-6 have proved that such drugs can significantly reduce the weight and cardiovascular risk of diabetic patients

Visceral and ectopic fat are key drivers of poor cardiometabolic outcomes in obesity

In this randomized, double-blind, placebo-controlled Phase 4 single-center trial, researchers recruited body mass index (BMI) ≥30kg/m2 or ≥27 kg/m2 from the University of Texas Southwestern Medical Center and had metabolism Adults with syndrome but no diabetes were randomly assigned at a ratio of 1:1 to receive a subcutaneous injection of liraglutide 3.

From July 20, 2017 to February 21, 2020, from 235 eligible participants, 185 participants were randomly assigned (n=92 liraglutide, n=93 placebo), 128 ( n=73 Liraglutide, n=55 placebo) were included in the final analysis (mean age 50.

Changes in VAT during treatment in the two groups

In the subgroups of age, gender, race-ethnicity, BMI, and baseline prediabetes, the effects appeared to be consistent

Among overweight or obese adults at high risk of cardiovascular disease, 3.

references:

Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.